Data from University of Toledo Advance Knowledge in Hypertrophic Cardiomyopathy (The Efficacy of Cardiac Myosin Inhibitors Versus Placebo In Patients With Symptomatic Hypertrophic Cardiomyopathy: a Meta-analysis and Systematic Review).

A meta-analysis and systematic review conducted by researchers at the University of Toledo in Ohio assessed the efficacy of cardiac myosin inhibitors in patients with symptomatic hypertrophic cardiomyopathy (HCM). The study included four randomized controlled trials involving 463 patients and found that compared to placebo, the cardiac myosin inhibitor group demonstrated statistically significant improvements in left ventricular outflow tract (LVOT) gradients, functional capacity, and New York Heart Association class improvement. However, there were potential negative effects on left ventricular ejection fraction (LVEF). The researchers concluded that further trials with larger sample sizes are needed to confirm these findings. [Extracted from the article]